News
ALZN
1.890
+2.72%
0.050
Alzamend Regains Compliance With Nasdaq Equity Requirement
NASDAQ · 4d ago
Alzamend Neuro Regains Nasdaq Compliance
Benzinga · 5d ago
Weekly Report: what happened at ALZN last week (0907-0911)?
Weekly Report · 09/14 09:55
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Benzinga · 09/10 21:23
Weekly Report: what happened at ALZN last week (0831-0904)?
Weekly Report · 09/07 09:50
Weekly Report: what happened at ALZN last week (0824-0828)?
Weekly Report · 08/31 09:55
Weekly Report: what happened at ALZN last week (0817-0821)?
Weekly Report · 08/24 09:56
Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
Benzinga · 08/21 20:51
Alzamend Neuro registers to sell 98.39M shares of common stock for holders
TipRanks · 08/21 20:35
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
Benzinga · 08/20 12:08
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 08/19 12:23
Alzamend Neuro Price Target Raised to $26.00/Share From $25.00 by Ascendiant Capital
Dow Jones · 08/19 10:16
Alzamend Neuro Is Maintained at Buy by Ascendiant Capital
Dow Jones · 08/19 10:16
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
Benzinga · 08/19 10:06
Weekly Report: what happened at ALZN last week (0810-0814)?
Weekly Report · 08/17 09:56
Weekly Report: what happened at ALZN last week (0803-0807)?
Weekly Report · 08/10 09:53
Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche
Benzinga · 08/04 12:12
Press Release: Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Dow Jones · 08/04 12:00
Alzamend Neuro Secures $25 Million Preferred Stock Financing
TipRanks · 08/03 22:38
Weekly Report: what happened at ALZN last week (0727-0731)?
Weekly Report · 08/03 09:53
More
Webull provides a variety of real-time ALZN stock news. You can receive the latest news about Alzamend Neuro Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.